

CONTENTS

	Page
Part one. General information	1
Notes	2
Introduction	3
Remarks on the statistical tables	3
English-French-Spanish index of names of countries and non-metropolitan territories	9
English-French-Spanish index of names of narcotic drugs	15
Part two. Comments on the reported statistics on narcotic drugs	19
Notes	20
Comments on the reported statistics on narcotic drugs	21
Part three. Supply of opiate raw materials and demand for opiates for medical and scientific purposes	117
Notes	118
Supply of opiate raw materials and demand for opiates for medical and scientific purposes	119
Part four. Statistical information on narcotic drugs	155
Notes	156
Tables of reported statistics	157
Table I. Cultivation of <i>Papaver somniferum</i> for the production of opium, 2017–2023	169
Table II. Cultivation of <i>Papaver somniferum</i> for purposes other than the production of opium, 2017–2023: production of poppy straw (M, T, C, N and O)	170
Table III. Extraction of alkaloids from opium, 2017–2021	176
Table IV. Extraction of morphine from poppy straw (M), 2017–2021	178
Table V. Extraction of thebaine from poppy straw (T and M), 2017–2021	182
Table VI. Conversion of morphine, 2017–2021	184
Table VII. Conversion of thebaine, 2017–2021	189
Table VIII. Manufacture of alkaloids contained in concentrate of poppy straw, 2017–2021	192
Table IX. Manufacture of the principal narcotic drugs, 2017–2021	194
Table X. Manufacture of other narcotic drugs, 2017–2021	199
1. Derivatives of opium alkaloids	199
2. Synthetic opioids	199
Table XI. Production, utilization, imports and exports of coca leaf and manufacture of cocaine, 2017–2021	200
Table XII. Consumption of the principal narcotic drugs and calculated consumption of buprenorphine, 2017–2021	202
Table XIII. Consumption of other narcotic drugs, 2017–2021	232
1. Fentanyl, principal fentanyl analogues and piritramide	232
2. Other derivatives of opium alkaloids	254
3. Other synthetic opioids	254
Table XIV. Levels of consumption of narcotic drugs, in defined daily doses for statistical purposes per million inhabitants per day, 2019–2021	255
1. Average consumption of narcotic drugs (excluding preparations in Schedule III) and calculated consumption of buprenorphine	255
a. All countries	255
b. Africa	263
c. Asia	265
d. Central America and the Caribbean	268
e. Europe	270
f. North America	272
g. Oceania	273
h. South America	275
i. All regions	276
2. Global average levels of utilization of narcotic drugs for the manufacture of preparations listed in Schedule III, in defined daily doses for statistical purposes per million inhabitants per day, 2012–2021	277
3. Global consumption of opioids, expressed in millions of defined daily doses for statistical purposes (S-DDD) 2002–2021..	278
Table XV. Total stocks of narcotic drugs, 2017–2021	280

Annexes*

I.	Status of adherence to international conventions on narcotic drugs and receipt of statistics (2021) and estimates (2023).....	285
Notes.....		286
Table		287
II.	Estimated requirements of narcotic drugs.....	297
Notes.....		298
Table A. Estimated world requirements of narcotic drugs for 2023.....		300
Table B. World totals of estimates, 2018–2023		342
III.	Comparative statement of estimates and statistics for 2021.....	345
Notes.....		346
Table		348
IV.	World trade, 2019–2021	467
Notes.....		468
1. Exports of opiate raw materials, 2019–2021		469
2. Imports of opiate raw materials, 2019–2021		471
3. Exports of the principal narcotic drugs, 2019–2021		474
4. Imports of the principal narcotic drugs, 2019–2021		482
V.	Seizures of selected narcotic drugs, 2021.....	503
Notes.....		504
Table		505

* As of 2018, the CD-Rom is no longer included in the printed version of this report. The report in its entirety, including the annexes, are available on the INCB website (www.incb.org).